Hematological Diseases and Therapies (ISSN: 2577-1418)

case report

  PDF Download

Synchronous Pneumonitis, Hepatitis and Enteritis Under Treatment with PI3kδ Inhibitor Idelalisib for Follicular Lymphoma

Maria Vergoulidou*, Diana Japaridze, Norbert Grobe

First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany

*Corresponding author: Maria Vergoulidou, First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany. Email: marivergi@yahoo.com

Received Date: 30 May, 2018; Accepted Date: 10 June, 2018; Published Date: 19 June, 2018

Citation: Vergoulidou M, Japaridze D, Grobe N (2018) Synchronous Pneumonitis, Hepatitis and Enteritis Under Treatment with PI3kδ Inhibitor Idelalisib for Follicular Lymphoma. Hem Disease Therapies: JHDT-115. DOI: 10.29011/2577-1418. 000015

1.                   Abstract

Idelalisib is approved for the treatment of relapsed follicular lymphoma. We report a case with multiple toxicities during treatment including pneumonitis, hepatitis and enteritis. Toxicities resolved under supportive treatment. Idelalisib was discontinued.  Our patient achieved partial remission of follicular lymphoma and had no further late complications. 

2.                   Keywords: Enteritis; Follicular Lymphoma Case Report; Hepatitis, Idelalisib; Pneumonitis


Figure 1: Elevation of transaminases (ALAT: serum alanine, ASAT: aspartate aminotransferase). Normal range 0,17-0,85 μmol/l.



Figure 2: Chest CT showing interstitial infiltrates and bilateral basal ground-glass opacities (upper image) and their resolution after a 3-month period (lower image).


Copyright and Licensing: This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. With this license readers can share, distribute, download, even commercially, as long as the original source is properly cited. Read More.

   

share article